Sign up for Breaking News Email Alerts

  • Neuralstem, NFL Alumni Association To Test Feasibility Of Traumatic Brain Injury Treatment

Reported in “Healthy Living,” Huffington Post, April 24, 2013

Neuralstem’s NSI-189/traumatic brain injury initiative announcement with the NFLA received widespread coverage, including this posting to The Huffington Post.

View Article

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

Privacy and Terms ©Neuralstem, Inc. 2014

Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research. | 8.1.14
The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online. | 7.30.14
FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology. | November 2013
FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured. | 11.20.13
Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189. | November-December 2013
Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.” | October 2013
FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial. | 8.28.13
Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.” | 5.30.13
MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury. | 9.13.12